



iCo Therapeutics Inc (TSX-V: 'ICO')

760-777 Hornby St.
Vancouver, BC

Tel: 604-602-9414
Fax: 604-602-9699

iCo-008 is a monoclonal antibody initially targeting severe eye allergies, with the potential to target additional billion dollar markets

iCo-008 has Multiple Therapeutic Opportunities

- iCo-008's initial target is allergic conjunctivitis, a **severe ocular allergy** affecting children and young adults that **can lead to permanent vision impairment**
- iCo-008 targets **more profound allergic conditions** than over-the-counter products
- The market for allergic conjunctivitis is a conservative \$50-70 Million
- Research indicates that iCo-008 may be effective in several **billion dollar markets**, including: food allergies, severe asthma, inflammatory bowel disease, allergic rhinitis & respiratory syncytial virus.
- iCo is in **active discussions with potential development partners** for these non-ocular indications.

What are iCo-008's advantages?

- iCo licensed the **exclusive world-wide rights** to iCo-008 from AstraZeneca/CAT
- iCo-008 has been in 126 patients in Phase I & II studies and has a **good safety profile**
- Nature of the disease allows for **rapid trials** and early results
- iCo-008 utilizes a targeted, highly specific biological approach
- Allergic conjunctivitis is common in Japan, Mediterranean basin (Italy, Spain, Israel), iCo has received expressions of interest from clinical investigators in these regions.

What is iCo-008's clinical plan?

- iCo-008 is ready for the **final stage of manufacturing** ("fill/finish")
- Re-activate IND prior to Phase II